Clarithromycin Patent Expiration
Clarithromycin is Used for treating mild to moderate infections caused by susceptible strains. It was first introduced by Abbvie Inc
Clarithromycin Patents
Given below is the list of patents protecting Clarithromycin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Biaxin Xl | US6551616 | Extended release formulations of erythromycin derivatives |
Jul 15, 2017
(Expired) | Abbvie |
| Biaxin Xl | US6010718 | Extended release formulations of erythromycin derivatives |
Apr 11, 2017
(Expired) | Abbvie |
Clarithromycin's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Clarithromycin:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
